LEGN

TentativeAI MemoPost-earnings T+3

Legend Biotech

As of 2026-08-14/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

—

Confidence

medium

Horizon

—

Key catalyst

LB2501 clinical proof-of-concept needs validation • 2026-11-12

Base target: $26 / p=50% prob

Biggest risk

The pipeline evidence is early, cash flow remained negative in the quarter, the company raised capital through a 7.7 million ADS offering, and the business remains highly dependent on CARVYKTI execution and the Janssen collaboration. Tax, regulatory, safety, partner, and clinical-development risks remain material. [#PR-2026-08-11]

Invalidation

Break below $15 or thesis failure.

What would change my mind?

The Q2 release materially improved operating evidence: CARVYKTI sales grew 50% year over year, profitability improved, access expanded, and LB2501 produced an early clinical proof-of-concept. The balance-sheet raise also extends financing flexibility. [#PR-2026-08-11]

Research note

Recommendation

—

Confidence

medium

As of

2026-08-14

Base target

$26

p=50%

Bull target

$38

p=25%

Bear target

$15

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 2026 showed commercial growth and first reported operating profit
CARVYKTI access expansion and profitability execution
The Q2 release materially improved operating evidence: CARVYKTI sales grew 50% year over year, profitability improved, access expanded, and LB2501 produced an early clinical proof-of-concept.

BearKey bullets

CARVYKTI concentration and dependence on continued commercial execution with Johnson & Johnson.
LB2102 remains a Phase 1 program with early clinical data and development risk.
LB2501 results are based on a small early-stage cohort and may not be durable or reproducible.

WatchKey bullets

LB2501 clinical proof-of-concept needs validation

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $26 (p=50%)

Target spread vs base: +46% / -42%

Scenario probabilities

Bull Target: $38 (p=25%)Base Target: $26 (p=50%)Bear Target: $15 (p=25%)

Commentary

The official Q2 release was operationally constructive, but the earnings packet contains no verified analyst revision breadth and no reliable post-release one-day market-reaction measure. The live quote remained near $20 on August 14, leaving the market response inconclusive. Deterministic evidence remains negative with high uncertainty, so the appropriate stance is cautious monitoring rather than a high-conviction re-rating thesis.

As of 2026-08-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 2026 showed commercial growth and first reported operating profit
CARVYKTI access expansion and profitability execution

Scenarios

Bull Target (Scenario probability)

$38 / p=25% prob

Base Target (Scenario probability)

$26 / p=50% prob

Bear Target (Scenario probability)

$15 / p=25% prob

Analysis 2026-08-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-11-12
LB2501 clinical proof-of-concept needs validation
The company reported 100% ORR and 83.3% complete response at the higher dose level in six relapsed/refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities reported. Larger cohorts, durability, and reproducibility remain key evidence requirements. [#PR-2026-08-11]
Prob 45.00% • Move 20.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Q2 2026 showed commercial growth and first reported operating profit
2026-08-11
Legend reported CARVYKTI net trade sales of approximately $657 million, up 50% year over year, operating income of $57.7 million versus a $21.9 million loss, and adjusted net income of $63.1 million versus $10.1 million. No trusted post-print consensus comparison or analyst revision was verified. [#PR-2026-08-11]
Prob 70% • Move 8% • Priced-in 55%

Long-term Catalysts

Months to a year

CARVYKTI access expansion and profitability execution
2027-08-14
CARVYKTI availability expanded to 348 global sites and 19 markets, while management said the approximately $965 million cash position supports runway beyond 2026 and continued progress toward company-wide adjusted profitability. Execution remains concentrated in one commercial franchise and partnership. [#PR-2026-08-11]
Prob 60% • Move 18% • Priced-in 45%

Risks

CARVYKTI concentration and dependence on continued commercial execution with Johnson & Johnson.
LB2102 remains a Phase 1 program with early clinical data and development risk.
LB2501 results are based on a small early-stage cohort and may not be durable or reproducible.
Operating cash flow was negative $20.9 million in Q2 2026, and the company disclosed uncertainty around the final outcome of its Chinese tax-authority pricing agreement.
Regulatory, safety, clinical-trial, intellectual-property, pricing, and partner-execution risks could delay or reduce expected growth. [#PR-2026-08-11]
The June public offering increased liquidity but diluted existing holders.

Peers

Symbol	Summary
GILD	Relevant benchmark through Kite and commercial cell-therapy infrastructure, but materially more diversified than LEGN and therefore only a loose valuation peer.
AMGN	Broad large-cap biotech comparator useful for framing sector sentiment and execution risk, but not a direct operating peer for LEGN's CAR-T franchise.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-14

Loading AI feed…

Symbol

Summary

GILD

Relevant benchmark through Kite and commercial cell-therapy infrastructure, but materially more diversified than LEGN and therefore only a loose valuation peer.

AMGN

Broad large-cap biotech comparator useful for framing sector sentiment and execution risk, but not a direct operating peer for LEGN's CAR-T franchise.